Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

0 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leuke
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... India , August 27, 2015 According ... Product (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, ... - Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling ... USD 411.5 Million in 2015, at a CAGR of 11.4 % ... 136 ma rket data T ables and ...
(Date:8/27/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the ... and patent-protected processes to develop and market advanced ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... inaccuracies in the press release issued by the ... from the Patent Trial and Appeal Board ("PTAB"). ...
(Date:8/27/2015)... According to a new market ... Standalone), by Deployment Mode (Web based, On-Premise, Cloud-Based), by ... Providers), by Component - Global Trends & Forecast to ... at $501.1 Million 2014, and is projected to reach ... from 2014 to 2019. Browse 60 ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
... Pharmaceuticals, Inc. (NASDAQ: AMPE ) ("Ampio" or ... uses for previously approved drugs and new molecular entities ... of the allowance of two important U.S. patents. The ... compounds that combine elements of diketopiperazines (same class as ...
... 2011 Reportlinker.com announces that a new ... catalogue: X-ray Equipment - ... http://www.reportlinker.com/p0683626/X-ray-Equipment---Top-5-European-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This package ... the following European countries: Germany, United Kingdom, ...
Cached Medicine Technology:Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases 2X-ray Equipment - Top 5 European Markets 2
(Date:8/27/2015)... Los Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... the most recent World Conference on Abdominal Wall Hernia Surgery involved many conversations between ... approved mesh options out there, the article notes that many different experts have different ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... exploding legal marijuana industry with the launch of its Doobster platform, a HIPAA-compliant ... to order products from their smart phones and tablets. Well, Doobster, “The ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is pleased to announce ... in San Jose, CA. The first event dedicated to finding alternative solutions ... exists where battery development and energy storage innovation are concerned. Product developers, ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in ... 2016. The new facility will be located at US Highway 19 North and Highlands Boulevard, ... August 18, and work on the project is slated to begin in September 2015. ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3
... The Mumbai-based Sun Pharmaceutical Industries entered the antismoking segment ... in Smoquit has been used for over a decade ... Rs. 13.50-per tablet priced Smoquit, the first pharmacotherapy ever ... prescription drug and is required to be taken under ...
... low testosterone levels in men suffering from eating ... affected more than women with the same problems, ... a weakening of the bones, which become dangerously thin ... and lack of essential nutrients, particularly calcium.Low bone mineral ...
... of proper nutrition while pregnant may be more likely to become ... from the University of Amsterdam looked at a group of 741 ... 1944-1945 which followed the Nazi occupation.// ,They found that ... when the study took place, was higher than in the general ...
... purple grape juice provides far greater antioxidant effects than ... journal of medicinal food. , The study states ... health through increased antioxidant consumption might prefer a glass ... juice," says Joe A. Vinson, professor of chemistry at ...
... men are at greater risk of developing heart disease than ... were published in the Archives of Internal Medicine, said they ... loss. ,The type of baldness also seemed to ... Those with frontal baldness had a 9% increased chance of ...
... supplement has been found to support immunity in elderly, ... every operation, rate of infection is a common risk, ... University of Pittsburgh report on the use of a ... undergoing surgery.// ,A group of 50 patients ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: